Short answer
AGIOS PHARMACEUTICALS, INC. (AGIO) filed its Q2 2026 10-Q quarterly report on Jul 30, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $45M (up 259.3% year over year) with net income of −$101M.
Q2 2026 key financials · XBRL
- Revenue
- $45M
- +259.3% YoY · +115.7% QoQ
- Net income
- −$101M
- +10.1% YoY · −1.6% QoQ
- Operating margin
- -247.1%
- EPS (diluted)
- −$1.69
- +12.9% YoY · +0.0% QoQ
Source: XBRL data from the AGIOS PHARMACEUTICALS, INC. (AGIO) Q2 2026 10-Q on SEC EDGAR. USD.
AGIOS PHARMACEUTICALS, INC. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- Newly triggered commercialization risk: AQVESME™ U.S. launch in late January 2026 introduced REMS-related prescribing and patient-access constraints
- Regulatory safety risk: AQVESME™ carries an FDA boxed warning for potential hepatocellular injury and requires an approved REMS
- Operational risk: Limited eligible populations and competitor trials could delay enrollment in genetically or biomarker-defined studies
- Competitive risk: Competing products approved for the same indications could reduce PYRUKYND® and AQVESME™ market acceptance
- Financial risk: Oscotec license adds up to $140.0 million in potential development and regulatory milestones plus royalties
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other AGIOS PHARMACEUTICALS, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.